#69: Our Take, September 9, 2019

Health Care Rounds

In today’s Our Take read-in, here’s the lead: “A judge ordered Johnson & Johnson to pay $572 million to Oklahoma for creating a ‘public nuisance.’ The state had sought $17.5 billion in a lawsuit against J&J, contending that the company had engaged in misleading marketing and contributed to the opioid epidemic that has claimed the lives of more than 6,000 Oklahomans. J&J plans to appeal, and the company’s shares rose in after-hours trading on the day of the ruling, suggesting that investors believed the outcome could have been much worse.” To sign up for the weekly email brief, click here.

Other briefs include:

• Capital Rx, a startup pharmacy benefit manager, launches its Clearinghouse Model.
• A federal judge officially approves the merger between CVS Health and Aetna.
• Michigan-based insurers Priority Health and Total Health Care will merge.
• Amgen will buy Celgene’s Otezla (apremilast), a psoriasis drug, for $13.4 billion.
• CMS rejects Idaho’s request for a waiver for Medicaid expansion.
• Blue Cross and Blue Shield of Minnesota announcea 5-year, value-based agreement with Minnesota Oncology.

About Darwin Research Group
Darwin Research Group Inc. provides advanced market intelligence and in-depth customer insights to health care executives, with a strategic focus on health care delivery systems and the global shift toward value-based care. Darwin’s client list includes forward-thinking biopharmaceutical and medical device companies, as well as health care providers, private equity, and venture capital firms. The company was founded in 2010 as Darwin Advisory Partners, LLC and is headquartered in Scottsdale, Ariz. with a satellite office in Princeton, N.J.

Get In Touch

Visit us

Follow:

Apple Podcasts

Spotify

Health Care Rounds on LinkedIn

Darwin Research Group on LinkedIn